Stoke TherapeuticsSTOK +5.09%45 Current Ratio is 8.99 as of Mar. 2026, which is 14% below its 10-year median of 10.46. GuruFocus rates STOK with a GF Score™ of 45/100 and a GF Value™ of $10.16 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,416 Biotechnology companies, Stoke Therapeutics ranks better than 74.86% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Stoke Therapeutics's current ratio for the quarter that ended in Mar. 2026 was 8.99.
Stoke Therapeutics has a current ratio of 8.99. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Stoke Therapeutics's Current Ratio or its related term are showing as below:
STOK'
s Current Ratio Range Over the Past 10 Years
Min: 0.51 Med: 10.46 Max: 55.12
Current: 8.99
During the past 9 years, Stoke Therapeutics's highest Current Ratio was 55.12. The lowest was 0.51. And the median was 10.46.
STOK's Current Ratio is ranked better than 74.86% of 1416
companies
in the Biotechnology industry
Industry Median: 3.885
vs STOK: 8.99
Stoke Therapeutics (NAS:STOK) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Stoke Therapeutics Current Ratio Related Terms
Stoke Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Stoke Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STOK vs SION, RXRX, VRDN: Current Ratio Comparison
For the Biotechnology subindustry, Stoke Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stoke Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stoke Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Stoke Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stoke Therapeutics (STOK) has a Current Ratio of 8.99 as of Mar. 2026. This is 14% below median its historical median of 10.46. Over the past decade, Stoke Therapeutics' Current Ratio has ranged from 0.51 to 55.12. According to the industry distribution chart, Stoke Therapeutics ranks #356 out of 1416 companies in the Biotechnology industry, placing it in the top 25.1%.
Is Stoke Therapeutics' Current Ratio too high?
Stoke Therapeutics' current Current Ratio of 8.99 is 14% below median its 10-year median of 10.46. Over the past 10 years, this metric has ranged from a low of 0.51 to a high of 55.12. The Biotechnology industry median Current Ratio is 3.89. Stoke Therapeutics' value of 8.99 is 131.4% above this industry median. Based on the distribution chart, Stoke Therapeutics ranks #356 out of 1416 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Stoke Therapeutics has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stoke Therapeutics' Current Ratio compare to SION and RXRX?
According to the Biotechnology industry distribution chart, Stoke Therapeutics ranks #356 out of 1416 companies for Current Ratio. This puts Stoke Therapeutics in the upper half of its industry. The industry median Current Ratio is 3.89. Stoke Therapeutics' value of 8.99 is 131.4% above this benchmark. Historically, Stoke Therapeutics' own Current Ratio has ranged from 0.51 to 55.12 over the past decade. While the company's 10-year median is 10.46 vs. the industry median of 3.89, Stoke Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stoke Therapeutics's current Current Ratio of 8.99 is 131.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stoke Therapeutics's current Current Ratio is 8.99, which is 14% below median its own 10-year median of 10.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stoke Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Stoke Therapeutics (STOK) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.16, compared to a current price of $31.90 — trading 214% above its estimated fair value. The current Current Ratio is 8.99, which is 14% below median its 10-year median of 10.46 and 131.4% above the Biotechnology industry median of 3.89. Stoke Therapeutics' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Stoke Therapeutics (STOK), the current Current Ratio is 8.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stoke Therapeutics (STOK) Overvalued in 2026?
Based on GuruFocus' analysis, Stoke Therapeutics stock appears to be overvalued.
The current stock price of $31.90 is trading 214% above its estimated GF Value™ of $10.16.
GuruFocus considers Stoke Therapeutics to be Significantly Overvalued.
Key valuation signals for STOK:
Current Ratio: 8.99 (14% below median its 10-year median of 10.46)
GF Value™: $10.16 vs. price of $31.90 (214% above fair value)
Industry Position: 131.4% above the Biotechnology median (#356 of 1416)
No single metric tells the full story. See the STOK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
45GF Score
Get the complete analysis for STOK
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STOK has been successfully added to your 
